does tirzepatide cause osteoporosis Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Effects of Semaglutide and Tirzepatide

The central mechanism is angiogenesis: the peptide upregulates vascular endothelial growth factor (VEGF) and drives new blood-vessel formation at injury sites, which brings oxygen and nutrients to healing tissue

Natures published research on incretin peptides provides foundational context for understanding both compounds mechanisms and investigational trajectories

Model-based predictions and corresponding 95% confidence intervals were generated across the full dose range

While Semaglutide is primarily studied as a GLP-1 receptor agonist, Tirzepatide is commonly researched because it interacts with both GLP-1 and GIP receptors